News Releases

Twist Bioscience Creates Custom Whole Exome Target Enrichment Panel for Canine Genomic Research

January 6, 2022

- Twist launches expert-designed panel that facilitates canine genomic research in partnership with Broad Institute Vertebrate Genomics Group

- Canine research could benefit research into several human diseases, including cancer –

SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 6, 2022-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced today an agreement with the Broad Institute to make available a whole exome target enrichment panel to enable next-generation sequencing (NGS) in canine genomics research. The panel, known as the Twist Alliance Canine Exome Panel, is available for order today and will begin shipping in February 2022.

The Twist Alliance Canine Exome is the most current commercial exome-scale assay available for canine NGS research, and is based on updated content from CanFam v3.1. The panel was collaboratively designed with the Vertebrate Genomics Group at the Broad Institute by leveraging Twist’s rapid, iterative and flexible NGS platform to provide a rapid, off-the-shelf solution covering all coding exons of canine genes. In addition to exon-centric content, the assay includes regions of known importance in human cancers. When used with Twist’s robust end-to-end target enrichment workflows it enables cost-effective comparative studies between human and canine genomics to drive further insight into both human and canine health.

“In addition to the benefits to dogs from research using our canine exome panels, there may also be implications for human health, as both canines and humans suffer from similar inherited diseases, such as cancer, heart disease, rheumatoid arthritis and autoimmune disorders,” said Emily M. Leproust, PhD, chief executive officer and co-founder of Twist Bioscience. “We are excited to expand our solutions in veterinary medicine, with the launch today of the Twist Alliance Canine Exome Panel.”

About Twist Alliance Panels

In partnership with leading research institutions from around the world, Twist has curated a collection of high-quality target enrichment panels for applications ranging from carrier screening to cancer diagnostics and whole exome sequencing. The Twist Alliance Panels combine the strengths of precise, highly uniform oligonucleotide synthesis with the specialty expertise of leading scientific research partners.

Well designed, custom target enrichment panels enable increased sequencing depth on target genes while reducing overall sequencing. This allows for more sensitive detection of target sequences and higher confidence variant detection.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; the retention of employees of acquired companies and the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits, risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Annual Report Form 10-K filed with the Securities and Exchange Commission on November 23, 2021 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Twist Bioscience
Angela Bitting
SVP, Corporate Affairs
925- 202-6211
media@twistbioscience.com

Source: Twist Bioscience Corporation